Andres Axel, Oldani Graziano, Berney Thierry, Compagnon Philippe, Line Pål-Dag, Toso Christian
Transplantation Division, Department of Surgery, Geneva University Hospital, Geneva, Switzerland.
Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Transl Gastroenterol Hepatol. 2018 Sep 26;3:74. doi: 10.21037/tgh.2018.08.04. eCollection 2018.
Liver transplantation (LT) has become the standard of care for selected primary and secondary malignancies. Considered a contra-indication to transplantation until recently, unresectable colorectal liver metastases (CRLM) have gained interest since the publication of the SECA trial by the University of Oslo. It showed a 5-year overall survival of 60%, comparable to the one of standard transplant indication. This report generated multiple questions about the place of LT for CRLM and gave raise to several trials aiming at answering them. The present review is exploring this topic, defining the current state of the field, and extrapolating the future milestones.
肝移植（LT）已成为特定原发性和继发性恶性肿瘤的标准治疗方法。直到最近，不可切除的结直肠癌肝转移（CRLM）一直被视为移植的禁忌症，但自奥斯陆大学发表SECA试验以来，它已引起了人们的关注。该试验显示5年总生存率为60%，与标准移植适应症的生存率相当。该报告引发了关于CRLM肝移植地位的多个问题，并催生了几项旨在回答这些问题的试验。本综述探讨了这一主题，界定了该领域的现状，并推断了未来的里程碑。
